Literature DB >> 8314564

The pattern of spontaneous germ-line mutation: relative rates of mutation at or near CpG dinucleotides in the factor IX gene.

C D Bottema1, R P Ketterling, E Vielhaber, H S Yoon, B Gostout, D P Jacobson, A Shapiro, S S Sommer.   

Abstract

Mutations at CpG dinucleotides were delineated in the factor IX gene of 38 hemophilia B patients. When transitions at CpG were considered with those previously reported by us and those compiled in the factor IX mutation database, the following patterns emerged. Many CpG sites were mutated with high frequency, while two CpG sites were infrequently mutated (R29-->Q and R116-->TGA). Of the 6 possible nonsense mutations and the 14 missense mutations that would produce a nonconservative change at conserved amino acids, all have been observed to cause hemophilia B except A-10-->T and R338-->Q. By contrast, none of the 6 missense changes at nonconserved amino acids have been observed to cause hemophilia B. At those CpG sites that are frequently mutated, the rate of transitions is estimated to be 20-fold higher than transitions at non-CpG sites. Point mutations in close proximity to CpG dinucleotides did not seem elevated.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8314564     DOI: 10.1007/bf00217779

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  35 in total

1.  "Founder" effect in different families with haemophilia B mutation.

Authors:  A R Thompson; S P Bajaj; S H Chen; R T MacGillivray
Journal:  Lancet       Date:  1990-02-17       Impact factor: 79.321

2.  Mutagen test.

Authors:  S S Sommer
Journal:  Nature       Date:  1990-07-05       Impact factor: 49.962

3.  Detection of polymorphisms at cytosine phosphoguanadine dinucleotides and diagnosis of haemophilia B carriers.

Authors:  P R Winship; D J Rees; M Alkan
Journal:  Lancet       Date:  1989-03-25       Impact factor: 79.321

Review 4.  The molecular basis of blood coagulation.

Authors:  B Furie; B C Furie
Journal:  Cell       Date:  1988-05-20       Impact factor: 41.582

5.  Alu repeats in the human factor IX gene: the rate of polymorphism is not substantially elevated.

Authors:  C M Dutton; C D Bottema; S S Sommer
Journal:  Hum Mutat       Date:  1993       Impact factor: 4.878

6.  Recognition site directing vitamin K-dependent gamma-carboxylation resides on the propeptide of factor IX.

Authors:  M J Jorgensen; A B Cantor; B C Furie; C L Brown; C B Shoemaker; B Furie
Journal:  Cell       Date:  1987-01-30       Impact factor: 41.582

7.  Why does the human factor IX gene have a G + C content of 40%?

Authors:  C D Bottema; M J Bottema; R P Ketterling; H S Yoon; R L Janco; J A Phillips; S S Sommer
Journal:  Am J Hum Genet       Date:  1991-10       Impact factor: 11.025

8.  The Pennsylvania hemophilia program 1973-1978.

Authors:  M E Eyster; J H Lewis; S S Shapiro; F Gill; M Kajani; D Prager; I Djerassi; S Rice; C Lusch; A Keller
Journal:  Am J Hematol       Date:  1980       Impact factor: 10.047

9.  The incidence and distribution of CpG----TpG transitions in the coagulation factor IX gene. A fresh look at CpG mutational hotspots.

Authors:  P M Green; A J Montandon; D R Bentley; R Ljung; I M Nilsson; F Giannelli
Journal:  Nucleic Acids Res       Date:  1990-06-11       Impact factor: 16.971

10.  Molecular pathology of haemophilia B.

Authors:  P M Green; D R Bentley; R S Mibashan; I M Nilsson; F Giannelli
Journal:  EMBO J       Date:  1989-04       Impact factor: 11.598

View more
  10 in total

1.  Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity.

Authors:  Benjamin J Samelson-Jones; Jonathan D Finn; Lindsey A George; Rodney M Camire; Valder R Arruda
Journal:  JCI Insight       Date:  2019-06-20

2.  The rates of G:C-->T:A and G:C-->C:G transversions at CpG dinucleotides in the human factor IX gene.

Authors:  R P Ketterling; E Vielhaber; S S Sommer
Journal:  Am J Hum Genet       Date:  1994-05       Impact factor: 11.025

Review 3.  DNA methylation: an alternative pathway to cancer.

Authors:  S A Wajed; P W Laird; T R DeMeester
Journal:  Ann Surg       Date:  2001-07       Impact factor: 12.969

4.  Haemophilia B: database of point mutations and short additions and deletions, fifth edition, 1994.

Authors:  F Giannelli; P M Green; S S Sommer; D P Lillicrap; M Ludwig; R Schwaab; P H Reitsma; M Goossens; A Yoshioka; G G Brownlee
Journal:  Nucleic Acids Res       Date:  1994-09       Impact factor: 16.971

5.  A de novo R589C mutation of anion exchanger 1 causing distal renal tubular acidosis.

Authors:  Suchai Sritippayawan; Sukachart Kirdpon; Somkiat Vasuvattakul; Sirijitta Wasanawatana; Watanachai Susaengrat; Worawee Waiyawuth; Sumalee Nimmannit; Prida Malasit; Pa-thai Yenchitsomanus
Journal:  Pediatr Nephrol       Date:  2003-05-16       Impact factor: 3.714

6.  Haemophilia B (sixth edition): a database of point mutations and short additions and deletions.

Authors:  F Giannelli; P M Green; S S Sommer; M C Poon; M Ludwig; R Schwaab; P H Reitsma; M Goossens; A Yoshioka; G G Brownlee
Journal:  Nucleic Acids Res       Date:  1996-01-01       Impact factor: 16.971

7.  Utilities for high throughput use of the single strand conformational polymorphism method: screening of 791 patients with familial hypercholesterolaemia for mutations in exon 3 of the low density lipoprotein receptor gene.

Authors:  R Whittall; V Gudnason; G P Weavind; L B Day; S E Humphries; I N Day
Journal:  J Med Genet       Date:  1995-07       Impact factor: 6.318

8.  Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants.

Authors:  Benjamin J Samelson-Jones; Jonathan D Finn; Leslie J Raffini; Elizabeth P Merricks; Rodney M Camire; Timothy C Nichols; Valder R Arruda
Journal:  Blood Adv       Date:  2021-03-09

Review 9.  Hemophilia B: molecular pathogenesis and mutation analysis.

Authors:  A C Goodeve
Journal:  J Thromb Haemost       Date:  2015-05-18       Impact factor: 5.824

Review 10.  Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy.

Authors:  Benjamin J Samelson-Jones; Valder R Arruda
Journal:  Mol Ther Methods Clin Dev       Date:  2018-12-31       Impact factor: 6.698

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.